Compare Nike Inc (NKE) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nike Inc vs Organon & Co. Common Stock — how do they compare? Nike Inc trades at $35.75 (market cap $52.43B), while Organon & Co. Common Stock trades at $13.73 (market cap $3.61B). The key difference: Nike Inc is far larger — about 14.5× Organon & Co. Common Stock's market cap, and Nike Inc pays the higher dividend (4.65%). Which is the better fit depends on your goals — on Pluang, investors hold Nike Inc for 155 Days and Organon & Co. Common Stock for 0 Days on average.
| NKE | OGN | |
|---|---|---|
Market Cap | $52.43B | $3.61B |
Volume | 19,378,123 | 1,808,049 |
Sector | Consumer Cyclical | Health |
52-Week High | $69.68 | $13.81 |
52-Week Low | $33.87 | $5.70 |
Typical Hold Time | 155 Days | 0 Days |
Enterprise Value | $55.14B | $11.03B |
Dividend Yield | 4.65% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NKE trades at $35.33, down slightly (-0.06%) on the day, with a bearish technical signal. The stock has a P/E of 16.9 and P/S of 1.14, trading below the analyst consensus price target of $36.80. Recent earnings have consistently beaten expectations, but revenue and net income have declined year-over-year. The company maintains strong brand equity but faces headwinds in key markets like China.
NKE's investment case hinges on its brand strength and potential for a turnaround, but near-term risks include sluggish consumer demand and margin pressure. The stock offers a dividend yield, but investors should weigh the execution risks of its strategic initiatives against its current valuation.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Nike Inc
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
